Trials / Terminated
TerminatedNCT04186637
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Alpine Immune Sciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALPN-202 | Multiple dose levels and dose regimens of ALPN-202 will be administered |
Timeline
- Start date
- 2020-06-02
- Primary completion
- 2022-11-09
- Completion
- 2023-02-28
- First posted
- 2019-12-05
- Last updated
- 2023-06-05
Locations
10 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04186637. Inclusion in this directory is not an endorsement.